Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Astrocytoma
  • Brain Neoplasms
  • Neoplasm Recurrence, Local
  • Radiosurgery

abstract

  • Bevacizumab with HFSRT is safe and well tolerated. Radiographic responses, duration of disease control, and survival suggest that this regimen is active in recurrent malignant glioma.

publication date

  • September 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3659401

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2008.10.043

PubMed ID

  • 19167838

Additional Document Info

start page

  • 156

end page

  • 63

volume

  • 75

number

  • 1